Quipt Home Medical Receives Final Order Approving Arrangement

Rhea-AI Summary

Quipt Home Medical (NASDAQ: QIPT) received a final court order from the Supreme Court of British Columbia approving a plan of arrangement under which affiliates of Kingswood Capital and Forager Capital will acquire all shares for US$3.65 per share.

Assuming remaining conditions are satisfied, closing is expected by March 16, 2026, after which the company anticipates delisting from the TSX and NASDAQ and ceasing to be a reporting issuer. Arrangement agreement dated Dec 14, 2025; shareholder materials filed on SEDAR+ and EDGAR.

Positive

• Final court approval obtained from the Supreme Court of British Columbia
• All-share acquisition offers US$3.65 per share in cash
• Expected transaction closing by March 16, 2026

Negative

• Shares anticipated to be delisted from TSX and NASDAQ post-closing
• Company expected to cease being a reporting issuer in all jurisdictions

Key Figures

Cash offer price: US$3.65 per Share Expected completion date: March 16, 2026

2 metrics

Cash offer price US$3.65 per Share Consideration under plan of arrangement

Expected completion date March 16, 2026 Target closing date for Arrangement

Market Reality Check

Price: $3.65 Vol: Volume 425,989 is 1.16x i...

normal vol

$3.65 Last Close

Volume Volume 425,989 is 1.16x its 20-day average of 367,140, typical for a closing-stage deal. normal

Technical Trading at the cash offer price of $3.65, above the $2.63 200-day MA and at its 52-week high.

Peers on Argus

QIPT is effectively pinned at the $3.65 cash offer with a small 0.27% move, whil...

2 Up 2 Down

QIPT is effectively pinned at the $3.65 cash offer with a small 0.27% move, while peers show mixed moves (e.g., ZYXI down 37.34%, SNYR up 2.29%). This pattern points to deal-specific trading rather than a unified sector trend.

Historical Context

5 past events · Latest: Mar 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	Shareholder vote results	Positive	+0.0%	Shareholders approved the cash arrangement at <b>$3.65</b> per share with strong support.
Feb 04	Proxy and interim order	Positive	+0.1%	Filed proxy materials and obtained interim court order for the <b>$3.65</b> cash deal vote.
Dec 15	Acquisition agreement	Positive	+34.1%	Entered definitive agreement to be acquired for <b>$3.65</b> per share in cash.
Dec 15	Earnings results	Positive	+34.1%	Reported Q4 and FY2025 growth with solid Adjusted EBITDA margins and cash flow.
Dec 05	Activist pressure	Positive	+2.5%	Concerned shareholder urged the board to pursue a value‑maximizing sale process.

Pattern Detected

Since announcing the cash buyout at $3.65, QIPT’s stock has largely tracked deal milestones, reacting strongly to the initial agreement and earnings, then stabilizing near the offer price as regulatory and shareholder approvals progressed.

Recent Company History

Over the last several months, Quipt Home Medical has moved steadily toward a go‑private transaction. A definitive acquisition agreement at $3.65 per share on Dec 15, 2025 and strong FY2025 results both coincided with sharp price gains. Subsequent filings and proxy materials in early 2026 detailed the Arrangement mechanics and shareholder vote process. Shareholders later approved the deal on Mar 3, 2026, and today’s final court order fits this sequence of closing conditions ahead of delisting and privatization.

Market Pulse Summary

This announcement confirms that the Supreme Court of British Columbia granted the final order for Qu...

Analysis

This announcement confirms that the Supreme Court of British Columbia granted the final order for Quipt’s plan of arrangement, under which buyers will acquire all shares for US$3.65 per Share. It follows earlier steps including the definitive agreement, regulatory filings, and shareholder approval. The news highlights an expected closing by March 16, 2026, after which the stock should be delisted and the company become non‑reporting, making the remaining execution timeline and any outstanding conditions key points to monitor.

Key Terms

plan of arrangement, delisted, reporting issuer, management information circular, +1 more

5 terms

plan of arrangement regulatory

"in connection with the previously announced plan of arrangement under the Business"

A plan of arrangement is a formal, court-approved agreement that reorganizes ownership or assets of a company—such as merging businesses, exchanging shares for cash or other securities, or splitting off parts of the company. Investors should care because it can change the value, number, and rights of their holdings and is often binding once approved by both shareholders and a court, offering more legal certainty than a simple vote. Think of it as a legally supervised recipe for how a company will be reshaped and who ends up with what.

delisted regulatory

"It is anticipated that the Shares will be delisted from the Toronto Stock Exchange"

Delisted means a company's shares have been removed from a public stock exchange and are no longer traded on that venue. For investors this matters because it reduces ease of buying or selling the stock, cuts off regular price discovery and exchange oversight, and can signal regulatory or financial problems; it's like a product being pulled from a supermarket shelf and only available through harder-to-find channels.

reporting issuer regulatory

"the Company will cease to be a reporting issuer in all jurisdictions in which it is"

A reporting issuer is a company or investment fund legally required to provide regular, public financial and corporate updates to securities regulators and investors. For investors it matters because those routine filings act like a business’s recurring health reports—offering consistent, official information to assess performance, risks and value so people can make informed buy, sell or compare decisions.

management information circular regulatory

"are further described in the Company’s management information circular and proxy"

A management information circular is a document sent to shareholders ahead of a company meeting that explains who is asking for votes, what decisions will be made, and why management recommends a particular outcome. Like an instruction booklet and argument sheet combined, it lays out details such as board nominees, executive pay, major transactions and any conflicts, helping investors decide how to vote and judge whether leadership choices could affect the company’s future value.

proxy statement regulatory

"management information circular and proxy statement dated January 23, 2026 and related"

A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.

AI-generated analysis. Not financial advice.

CINCINNATI, March 05, 2026 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT; TSX: QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, announces that the Supreme Court of British Columbia issued a final order today in connection with the previously announced plan of arrangement under the Business Corporations Act (British Columbia) (the “Arrangement”) pursuant to which affiliates of Kingswood Capital Management, L.P. and Forager Capital Management, LLC will acquire all of the issued and outstanding common shares of the Company (each, a “Share”) for cash consideration of US$3.65 per Share. The final order was the final substantive court approval required prior to the closing of the Arrangement. Assuming all other terms and conditions to the Arrangement are satisfied, it is expected that the Arrangement will be completed by March 16, 2026.

It is anticipated that the Shares will be delisted from the Toronto Stock Exchange (“TSX”) and the Nasdaq Capital Markets (“NASDAQ”) and that the Company will cease to be a reporting issuer in all jurisdictions in which it is a reporting issuer under applicable securities laws, in each case shortly after completion of the Arrangement.

The terms of the Arrangement and the arrangement agreement among the Company, 1567208 B.C. Ltd. and REM Aggregator, LLC dated December 14, 2025 are further described in the Company’s management information circular and proxy statement dated January 23, 2026 and related materials for the special meeting of shareholders of the Company held on March 3, 2026, all of which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.

ABOUT QUIPT HOME MEDICAL CORP.‎

The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to offer a broader range of services to patients in need of in-home monitoring and chronic disease management.

FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “postulate”, “expect”, “outlook”, or the negatives thereof or variations of such words, and similar expressions as they relate to the Company are intended to identify forward-looking statements, including: the proposed Arrangement and terms thereof; and other statements that are not historical fact. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions, including, without limitation: the ability to obtain the necessary regulatory and other third party approvals for the Arrangement, the timing of obtaining such approvals and the risk that such approvals may not be obtained in a timely manner or at all, and the risk that such approvals may be obtained on conditions that are not anticipated; the anticipated completion of the Arrangement and timing thereof; the abilities of the parties to satisfy, in a timely manner, the other conditions to the closing of the Arrangement; the delisting of the Shares from the TSX and NASDAQ; the Company ceasing to be a reporting issuer under Canadian and U.S. federal securities laws and the timing thereof; the failure of the Arrangement to close for any other reason; and the ability to achieve the expected benefits of the Arrangement. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. Examples of such risk factors include, without limitation: risks related to credit, market (including equity, commodity, foreign exchange and interest rate), liquidity, operational (including technology and infrastructure), reputational, insurance, strategic, regulatory, legal, environmental, and capital adequacy; the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; the ability to implement business strategies and pursue business opportunities; low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company’s information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; decline of reimbursement rates; dependence on few payors; possible new drug discoveries; a novel business model; dependence on key suppliers; granting of permits and licenses in a highly regulated business; legal proceedings and litigation, including as it relates to the civil investigative demand received from the Department of Justice; increased competition; changes in foreign currency rates; the imposition of trade restrictions such as tariffs and retaliatory counter measures; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company’s status as an emerging growth company and a smaller reporting company; the occurrence of natural and unnatural catastrophic events or health epidemics or concerns; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the SEC and available on EDGAR at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada and available at www.sedarplus.ca. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statement prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

For further information please visit our website at www.quipthomemedical.com, or contact:‎

Cole Stevens
VP of Corporate Development
Quipt Home Medical Corp.
‎859-300-6455
cole.stevens@myquipt.com

Gregory Crawford
Chief Executive Officer
Quipt Home Medical Corp.
‎859-300-6455
investorinfo@myquipt.com

FAQ

What did Quipt (QIPT) announce about the final court order on March 5, 2026?

The company said it received a final order from the Supreme Court of British Columbia approving the arrangement. According to the company, that order was the final substantive court approval required before the Arrangement can close.

How much are buyers paying per share in the QIPT arrangement and who are the buyers?

Buyers will pay US$3.65 per share in cash, the company announced. According to the company, affiliates of Kingswood Capital Management and Forager Capital Management are the acquiring parties.

When is the Quipt (QIPT) transaction expected to close and what is the timeline?

Assuming remaining conditions are satisfied, closing is expected by March 16, 2026. According to the company, that date follows the final court order and completion of customary closing conditions.

Will Quipt (QIPT) remain listed on TSX and NASDAQ after the Arrangement closes?

No, the company expects the shares to be delisted from TSX and NASDAQ shortly after closing. According to the company, it also anticipates ceasing to be a reporting issuer in all jurisdictions.

Where can QIPT shareholders find the arrangement agreement and related materials?

Shareholder materials, including the arrangement agreement and proxy statement, are available on SEDAR+ and EDGAR. According to the company, those filings include the detailed terms dated December 14, 2025 and the March 3, 2026 meeting materials.